Mereo BioPharma (MREO) Convertible Debt (2023)
Mereo BioPharma (MREO) posted quarterly Convertible Debt of $4.4 million for Q4 2023.
Mereo BioPharma (MREO) Convertible Debt (2023) Analysis & Trends
Mereo BioPharma (MREO) has reported Convertible Debt for 1 consecutive years, with $4.4 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Convertible Debt changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2023 stood at $4.4 million (changed N/A YoY), while the FY2023 annual figure was $4.4 million, changed N/A from the prior year.
- Convertible Debt was little changed at $4.4 million in Q4 2023 per MREO's latest filing.
- Across five years, Convertible Debt topped out at $4.4 million in Q4 2023 and bottomed at $4.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.39 Mn |